Literature DB >> 27868338

Incomplete Timothy syndrome secondary to a mosaic mutation of the CACNA1C gene diagnosed using next-generation sequencing.

Amandine Baurand1, Sylvie Falcon-Eicher2,3, Gabriel Laurent3, Elisabeth Villain4, Caroline Bonnet2,3, Christel Thauvin-Robinet1, Caroline Jacquot1, Jean-Christophe Eicher3, Jean-Baptiste Gourraud5, Sébastien Schmitt6, Stéphane Bézieau6, Mathilde Giraud6, Solenne Dumont6, Paul Kuentz7, Vincent Probst5, Antoine Burguet8, Florence Kyndt5,6, Laurence Faivre1,3,7.   

Abstract

Autosomal dominant genetic diseases can occur de novo and in the form of somatic mosaicism, which can give rise to a less severe phenotype, and make diagnosis more difficult given the sensitivity limits of the methods used. We report the case of female child with a history of surgery for syndactyly of the hands and feet, who was admitted at 6 years of age to a pediatric intensive care unit following cardiac arrest. The electrocardiogram (ECG) showed a long QT interval that on occasions reached 500 ms. Despite the absence of facial dysmorphism and the presence of normal psychomotor development, a diagnosis of Timothy syndrome was made given the association of syndactyly and the ECG features. Sanger sequencing of the CACNA1C gene, followed by sequencing of the genes KCNQ1, KCNH2, KCNE1, KCNE2, were negative. The subsequent analysis of a panel of genes responsible for hereditary cardiac rhythm disorders using Haloplex technology revealed a recurrent mosaic p.Gly406Arg missense mutation of the CACNA1C gene in 18% of the cells. This mosaicism can explain the negative Sanger analysis and the less complete phenotype in this patient. Given the other cases in the literature, mosaic mutations in Timothy syndrome appear more common than previously thought. This case demonstrates the importance of using next-generation sequencing to identify mosaic mutations when the clinical picture supports a specific mutation that is not identified using conventional testing.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  CACNA1C; Timothy syndrome; long-QT; mosaic mutation; next-generation sequencing; syndactyly

Mesh:

Substances:

Year:  2016        PMID: 27868338     DOI: 10.1002/ajmg.a.38045

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  Dysfunctional Cav1.2 channel in Timothy syndrome, from cell to bedside.

Authors:  Dan Han; Xiaolin Xue; Yang Yan; Guoliang Li
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-19

2.  Next-generation sequencing corroborates a probable de novo GNPTG variation previously detected by Sanger sequencing.

Authors:  Nataniel Floriano Ludwig; Fernanda Sperb-Ludwig; Renata Voltolini Velho; Ida Vanessa D Schwartz
Journal:  Mol Genet Metab Rep       Date:  2017-03-01

Review 3.  Voltage-Gated Ca2+-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies.

Authors:  Jörg Striessnig
Journal:  Front Synaptic Neurosci       Date:  2021-03-03

4.  Hyperinsulinemic Hypoglycemia Associated with a CaV1.2 Variant with Mixed Gain- and Loss-of-Function Effects.

Authors:  Sebastian Kummer; Susanne Rinné; Gunnar Seemann; Nadine Bachmann; Katherine Timothy; Paul S Thornton; Frank Pillekamp; Ertan Mayatepek; Carsten Bergmann; Thomas Meissner; Niels Decher
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

Review 5.  Update on the Molecular Genetics of Timothy Syndrome.

Authors:  Rosemary Bauer; Katherine W Timothy; Andy Golden
Journal:  Front Pediatr       Date:  2021-05-17       Impact factor: 3.418

6.  Penetrance and expressivity of the R858H CACNA1C variant in a five-generation pedigree segregating an arrhythmogenic channelopathy.

Authors:  R J McKinlay Gardner; Ian G Crozier; Alex L Binfield; Donald R Love; Klaus Lehnert; Kate Gibson; Caroline J Lintott; Russell G Snell; Jessie C Jacobsen; Peter P Jones; Kathryn E Waddell-Smith; Martin A Kennedy; Jonathan R Skinner
Journal:  Mol Genet Genomic Med       Date:  2018-10-21       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.